News, updates, and early warnings from the front lines of datacenter infrastructure. That kind of thing.
Cloud
When you’re operating at 10 quadrillion biomolecular data points, terms like scale and complexity almost lose their punch. Right down the street from Microsoft, Bellevue-based Viome Life Sciences, tapped Azure to help manage one of the largest RNA datasets in existence, gathered from over one million biological samples collected
Drug Discovery
At the heart of drug discovery there’s a paradox both frustrating and familiar to anyone steeped in pharmaceutical research: the vast oceans of preclinical data that flood in from assays, structural analyses, and early molecular testing. All of this contrasts starkly with the scarce trickle of clinical data that
Data
In the endlessly recursive world of drug development, where billions are burned chasing molecules that never make it to market, the idea of conjuring promising compounds from nothing has always been more hope than method. Until this week. SandboxAQ, a company born out of Alphabet and now backed by Nvidia
News
The biotech industry, never short on acronyms or ambition, has been flirting with artificial intelligence for years. Models have already been shaping protocol designs, accelerated site selection, and sifted through trial data faster than any human team could hope to match. But until recently, these systems operated in a kind
Data
Xaira just dropped X-Atlas/Orion—the largest genome-wide Perturb-seq dataset ever, covering 8 million cells. It's public, powerful, and poised to reshape how AI predicts biology. Launching a biotech startup is often about making promises. These are promises to investors, to science, to medicine. But when you start
AI
Fauna Bio is betting evolution already cracked biology’s toughest problems. Their new AI engine, Fauna Brain, turns nature’s wildest genetic secrets into therapeutic targets in minutes and costs pennies. Fauna Bio isn’t your typical Silicon Valley biotech startup. Instead of chasing incremental tweaks to familiar targets, they&
News
AstraZeneca is placing a $110 million direct bet on CSPC Pharmaceuticals AI platform in Shijiazhuang. It’s not about factories or sales, it’s about code. CSPC, which few in the West have heard of and which has only a small trace on the web, will power discovery with a